Go Pro
→ They're shrinking your dollars every single month (From American Alternative) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 1.94 +0.06 (+3.20%)
As of 07:15 AM Eastern
Compare

GENF vs. HVO, COIL, HEMO, C4XD, and DDDD

Should you buy Genflow Biosciences stock or one of its competitors? Genflow Biosciences's main competitors and comparable companies include hVIVO (HVO), Roquefort Therapeutics (COIL), Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to hVIVO?

hVIVO (LON:HVO) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 137.68%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts plainly believe hVIVO is more favorable than Genflow Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Genflow Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

hVIVO has higher revenue and earnings than Genflow Biosciences. hVIVO is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£38.85M1.12£17.84M-£0.87N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

In the previous week, hVIVO had 3 more articles in the media than Genflow Biosciences. MarketBeat recorded 3 mentions for hVIVO and 0 mentions for Genflow Biosciences. hVIVO's average media sentiment score of 0.14 beat Genflow Biosciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Neutral
Genflow Biosciences Neutral

hVIVO has a beta of 1.694, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, suggesting that its share price is 129% more volatile than the broader market.

hVIVO has a net margin of -31.76% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-31.76% -35.13% 11.97%
Genflow Biosciences -170.64%332.06%-58.66%

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

hVIVO beats Genflow Biosciences on 10 of the 15 factors compared between the two stocks.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, indicating that its share price is 129% more volatile than the broader market.

In the previous week, Roquefort Therapeutics had 3 more articles in the media than Genflow Biosciences. MarketBeat recorded 3 mentions for Roquefort Therapeutics and 0 mentions for Genflow Biosciences. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Genflow Biosciences Neutral

1.8% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Genflow Biosciences -170.64%332.06%-58.66%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Summary

Roquefort Therapeutics beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Genflow Biosciences is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Hemogenyx Pharmaceuticals has a beta of 1.487, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, suggesting that its stock price is 129% more volatile than the broader market.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Genflow Biosciences -170.64%332.06%-58.66%

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Genflow Biosciences Neutral

Summary

Hemogenyx Pharmaceuticals beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 27.1% of C4X Discovery shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

C4X Discovery has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.285, suggesting that its stock price is 129% more volatile than the broader market.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences -170.64%332.06%-58.66%

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

Genflow Biosciences (LON:GENF) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled 4D pharma'saverage media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
4D pharma Neutral

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 26.8% of 4D pharma shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by company insiders. Comparatively, 12.2% of 4D pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genflow Biosciences has a beta of 2.285, indicating that its stock price is 129% more volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market.

4D pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
4D pharma N/A -89.48%-42.64%

Genflow Biosciences has higher earnings, but lower revenue than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
4D pharma£718K0.00-£31.94M-£15.40N/A

Summary

4D pharma beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£10.98M£3.98B£7.31B£2.89B
Dividend YieldN/A3.63%2.52%6.22%
P/E Ratio-5.8413.88274.08366.58
Price / SalesN/A1,343.77638.2190,067.79
Price / Cash3.00113.2977.8027.89
Price / Book7.8115.4010.476.41
Net Income-£1.76M-£22.82M£3.49B£5.89B
7 Day Performance-0.56%-1.70%-0.67%0.29%
1 Month Performance-5.41%-6.17%-3.17%6.48%
1 Year Performance5.96%30.67%15.14%19.36%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 1.94
+3.2%		N/A+30.2%£10.96MN/AN/A5
HVO
hVIVO
1.6556 of 5 stars		GBX 6.09
+1.5%		GBX 15
+146.4%		-25.5%£41.90M£38.85MN/AN/A
COIL
Roquefort Therapeutics
N/AGBX 7.60
-5.0%		N/A-52.9%£32.44MN/AN/A9
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 467
-0.6%		N/A-68.4%£31.76MN/AN/A14
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel